MANE Veradermics | $92.01
+1.2% | 6/16/2026 | | Initiated Coverage | $135.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Veradermics (NYSE:MANE) on 6/16/2026 |
NUVL Nuvalent | $123.43
+0.0% | 6/9/2026 | | Downgrade | $124.00 | Outperform ➝ Hold | 00.00% | View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 6/9/2026 |
RCUS Arcus Biosciences | $23.97
+1.8% | 6/4/2026 | | Initiated Coverage | $46.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Arcus Biosciences (NYSE:RCUS) on 6/4/2026 |
ACRS Aclaris Therapeutics | $4.34
+0.1% | 6/2/2026 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Aclaris Therapeutics (NASDAQ:ACRS) on 6/2/2026 |
ACRS Aclaris Therapeutics | $4.34
+0.1% | 6/1/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aclaris Therapeutics (NASDAQ:ACRS) on 6/1/2026 |
KRRO Korro Bio | $10.91
+2.4% | 5/29/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Korro Bio (NASDAQ:KRRO) on 5/29/2026 |
SLGL Sol-Gel Technologies | $71.45
-3.2% | 5/15/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Sol-Gel Technologies (NASDAQ:SLGL) on 5/15/2026 |
MPLT Maplight Therapeutics | $27.79
-0.6% | 5/14/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Maplight Therapeutics (NASDAQ:MPLT) on 5/14/2026 |
IMUX Immunic | $13.89
+1.3% | 5/4/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Immunic (NASDAQ:IMUX) on 5/4/2026 |
STRO Sutro Biopharma | $28.35
-6.1% | 5/1/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Sutro Biopharma (NASDAQ:STRO) on 5/1/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
INBX Inhibrx Biosciences | $94.69
+1.7% | 4/24/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 4/24/2026 |
CNTA Centessa Pharmaceuticals | $39.74
0.0% | 4/1/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 4/1/2026 |
MBX MBX Biosciences | $40.42
+0.8% | 3/31/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of MBX Biosciences (NASDAQ:MBX) on 3/31/2026 |
MREO Mereo BioPharma Group | $0.30
+2.1% | 3/19/2026 | | Upgrade | | Hold | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 3/19/2026 |
TARS Tarsus Pharmaceuticals | $62.04
+0.3% | 3/16/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 3/16/2026 |
TENX Tenax Therapeutics | $11.58
+2.2% | 3/12/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tenax Therapeutics (NASDAQ:TENX) on 3/12/2026 |
JBIO Jade Biosciences | $15.83
+1.9% | 3/6/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Jade Biosciences (NASDAQ:JBIO) on 3/6/2026 |
LQDA Liquidia | $69.72
+2.5% | 3/5/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 3/5/2026 |
TNYA Tenaya Therapeutics | $0.72
+6.0% | 3/5/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/5/2026 |
PRME Prime Medicine | $3.14
+9.2% | 3/2/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 3/2/2026 |
RCKT Rocket Pharmaceuticals | $3.03
+8.0% | 2/26/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 2/26/2026 |
SION Sionna Therapeutics | $34.82
+0.2% | 2/25/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 2/25/2026 |
LRMR Larimar Therapeutics | $3.58
+5.3% | 2/24/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/24/2026 |
CNTX Context Therapeutics | $0.60
-7.7% | 2/23/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Context Therapeutics (NASDAQ:CNTX) on 2/23/2026 |
IKT Inhibikase Therapeutics | $1.70
+1.5% | 2/23/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Inhibikase Therapeutics (NASDAQ:IKT) on 2/23/2026 |
CRNX Crinetics Pharmaceuticals | $35.63
+1.8% | 2/13/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 2/13/2026 |
CMPS Compass Pathways | $11.78
+2.5% | 2/12/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Compass Pathways (NASDAQ:CMPS) on 2/12/2026 |
IRD Opus Genetics | $3.90
+0.1% | 2/12/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Opus Genetics (NASDAQ:IRD) on 2/12/2026 |
TECX Tectonic Therapeutic | $30.45
+3.6% | 2/5/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 2/5/2026 |
DMRA Damora Therapeutics, Inc. Common Stock | $20.51
-0.4% | 2/2/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 2/2/2026 |
NGNE Neurogene | $29.65
+1.0% | 1/26/2026 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Neurogene (NASDAQ:NGNE) on 1/26/2026 |
MREO Mereo BioPharma Group | $0.30
+2.1% | 12/29/2025 | | Downgrade | | Outperform ➝ Hold | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/29/2025 |
PRME Prime Medicine | $3.14
+9.2% | 12/23/2025 | | Initiated Coverage | $6.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 12/23/2025 |
PRME Prime Medicine | $3.14
+9.2% | 12/23/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 12/23/2025 |
SION Sionna Therapeutics | $34.82
+0.2% | 12/23/2025 | | Initiated Coverage | $60.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 12/23/2025 |
OVID Ovid Therapeutics | $2.37
+0.2% | 12/22/2025 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Ovid Therapeutics (NASDAQ:OVID) on 12/22/2025 |
IBIO iBio | $1.53
-1.6% | 12/18/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of iBio (NASDAQ:IBIO) on 12/18/2025 |
MAZE Maze Therapeutics | $24.35
+0.3% | 12/18/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Maze Therapeutics (NASDAQ:MAZE) on 12/18/2025 |
EPRX Eupraxia Pharmaceuticals | $6.30
+4.4% | 12/11/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 12/11/2025 |
OCS Oculis | $11.27
-1.6% | 12/3/2025 | | Initiated Coverage | $55.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Oculis (NASDAQ:OCS) on 12/3/2025 |
SpaceX will mint billionaires. You won't be one of them. (Ad) By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion.
But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free. Get the ticker before Wall Street connects the dots |
UPB Upstream Bio | $6.03
+1.9% | 12/2/2025 | | Initiated Coverage | $43.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Upstream Bio (NASDAQ:UPB) on 12/2/2025 |
IKT Inhibikase Therapeutics | $1.70
+1.5% | 12/1/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Inhibikase Therapeutics (NASDAQ:IKT) on 12/1/2025 |
ADAG Adagene | $3.44
-2.0% | 11/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Adagene (NASDAQ:ADAG) on 11/14/2025 |
KLC KinderCare Learning Companies | $3.82
+0.4% | 11/13/2025 | | Reiterated Rating | | Market Perform | 00.00% | View details for Lifesci Capital rating of KinderCare Learning Companies (NYSE:KLC) on 11/13/2025 |
SRZN Surrozen | $23.22
+2.1% | 11/13/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Surrozen (NASDAQ:SRZN) on 11/13/2025 |
AMLX Amylyx Pharmaceuticals | $15.39
+2.2% | 10/27/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/27/2025 |
KOD Kodiak Sciences | $34.88
+5.9% | 10/23/2025 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Kodiak Sciences (NASDAQ:KOD) on 10/23/2025 |
CADL Candel Therapeutics | $7.98
+0.1% | 10/21/2025 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Candel Therapeutics (NASDAQ:CADL) on 10/21/2025 |
DFTX Definium Therapeutics | $24.40
+1.0% | 10/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Definium Therapeutics (NASDAQ:DFTX) on 10/14/2025 |
DYN Dyne Therapeutics | $19.27
+6.6% | 10/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 10/14/2025 |
SVRA Savara | $5.42
+2.3% | 10/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Savara (NASDAQ:SVRA) on 10/14/2025 |
CMPX Compass Therapeutics | $2.04
+3.3% | 10/6/2025 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Compass Therapeutics (NASDAQ:CMPX) on 10/6/2025 |
KALA KALA BIO | $3.31
+5.3% | 9/29/2025 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of KALA BIO (NASDAQ:KALA) on 9/29/2025 |
GPCR Structure Therapeutics | $44.02
+2.6% | 9/8/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 9/8/2025 |
AQST Aquestive Therapeutics | $4.26
-0.1% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/3/2025 |
CNTA Centessa Pharmaceuticals | $39.74
0.0% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 9/3/2025 |
KALA KALA BIO | $3.31
+5.3% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of KALA BIO (NASDAQ:KALA) on 9/3/2025 |
PRAX Praxis Precision Medicines | $269.16
+4.6% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Praxis Precision Medicines (NASDAQ:PRAX) on 9/3/2025 |
RVMD Revolution Medicines | $159.24
+1.7% | 8/18/2025 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Revolution Medicines (NASDAQ:RVMD) on 8/18/2025 |
PVLA Palvella Therapeutics | $112.20
+1.9% | 8/4/2025 | | Initiated Coverage | $90.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 8/4/2025 |
VYNE VYNE Therapeutics | $0.64
+2.4% | 7/30/2025 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 7/30/2025 |
ABVX Abivax | $99.12
+1.7% | 7/23/2025 | | Boost Price Target | $45.00 ➝ $101.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Abivax (NASDAQ:ABVX) on 7/23/2025 |
CATX Perspective Therapeutics | $2.97
+1.2% | 7/12/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 7/12/2025 |
CRBP Corbus Pharmaceuticals | $8.18
+3.8% | 7/12/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 7/12/2025 |
DBVT DBV Technologies | $16.88
+0.8% | 6/26/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of DBV Technologies (NASDAQ:DBVT) on 6/26/2025 |
CBIO Crescent Biopharma | $18.03
+0.4% | 6/18/2025 | | Upgrade | $22.00 | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 6/18/2025 |
TECX Tectonic Therapeutic | $30.45
+3.6% | 6/6/2025 | | Initiated Coverage | $87.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/6/2025 |
TECX Tectonic Therapeutic | $30.45
+3.6% | 6/5/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/5/2025 |
SRRK Scholar Rock | $47.18
+3.5% | 6/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Scholar Rock (NASDAQ:SRRK) on 6/3/2025 |
GLUE Monte Rosa Therapeutics | $18.54
+4.4% | 3/12/2025 | | Initiated Coverage | $19.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Monte Rosa Therapeutics (NASDAQ:GLUE) on 3/12/2025 |
IMNM Immunome | $18.12
+1.2% | 3/11/2025 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Immunome (NASDAQ:IMNM) on 3/11/2025 |
MOLN Molecular Partners | $4.01
+2.3% | 3/11/2025 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Molecular Partners (NASDAQ:MOLN) on 3/11/2025 |
TARA Protara Therapeutics | $3.99
+4.8% | 3/11/2025 | | Initiated Coverage | $22.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Protara Therapeutics (NASDAQ:TARA) on 3/11/2025 |
ZYME Zymeworks | $23.03
+2.4% | 3/11/2025 | | Initiated Coverage | $30.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Zymeworks (NASDAQ:ZYME) on 3/11/2025 |
CATX Perspective Therapeutics | $2.97
+1.2% | 3/6/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 3/6/2025 |
AURA Aura Biosciences | $6.43
+2.3% | 1/31/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 1/31/2025 |
JANX Janux Therapeutics | $14.01
+2.2% | 12/27/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Janux Therapeutics (NASDAQ:JANX) on 12/27/2024 |
MREO Mereo BioPharma Group | $0.30
+2.1% | 12/24/2024 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/24/2024 |
MREO Mereo BioPharma Group | $0.30
+2.1% | 12/23/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/23/2024 |
KURA Kura Oncology | $9.64
+2.6% | 10/22/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Kura Oncology (NASDAQ:KURA) on 10/22/2024 |
OKUR OnKure Therapeutics | $4.20
-1.3% | 10/10/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of OnKure Therapeutics (NASDAQ:OKUR) on 10/10/2024 |
LQDA Liquidia | $69.72
+2.5% | 10/3/2024 | | Initiated Coverage | $30.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/3/2024 |
LQDA Liquidia | $69.72
+2.5% | 10/2/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/2/2024 |
ORKA Oruka Therapeutics | $69.91
+3.3% | 9/16/2024 | | Initiated Coverage | $41.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/16/2024 |
AURA Aura Biosciences | $6.43
+2.3% | 9/9/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 9/9/2024 |
CELC Celcuity | $87.20
-0.1% | 8/26/2024 | | Initiated Coverage | $27.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Celcuity (NASDAQ:CELC) on 8/26/2024 |
CRBP Corbus Pharmaceuticals | $8.18
+3.8% | 8/21/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 8/21/2024 |
ALXO ALX Oncology | $1.44
+4.0% | 7/31/2024 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 7/31/2024 |
IDYA IDEAYA Biosciences | $30.73
+0.5% | 7/29/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of IDEAYA Biosciences (NASDAQ:IDYA) on 7/29/2024 |
NUVL Nuvalent | $123.43
+0.0% | 7/29/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Nuvalent (NASDAQ:NUVL) on 7/29/2024 |
Trump's gold order: the announcement they won't put on the front page (Ad) On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade.
Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction.
A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. Request the free guide in 30 seconds and get positioned now |
DNTH Dianthus Therapeutics | $80.30
+1.8% | 6/11/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Dianthus Therapeutics (NASDAQ:DNTH) on 6/11/2024 |
CALT Calliditas Therapeutics AB (publ) | $40.00
| 5/28/2024 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 5/28/2024 |
CATX Perspective Therapeutics | $2.97
+1.2% | 5/6/2024 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 5/6/2024 |
MLYS Mineralys Therapeutics | $25.13
+4.8% | 3/26/2024 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Mineralys Therapeutics (NASDAQ:MLYS) on 3/26/2024 |
GPCR Structure Therapeutics | $44.02
+2.6% | 2/27/2024 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 2/27/2024 |
LRMR Larimar Therapeutics | $3.58
+5.3% | 2/20/2024 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/20/2024 |
INBX Inhibrx Biosciences | $94.69
+1.7% | 1/23/2024 | | Downgrade | | Outperform ➝ Market Perform | 00.00% | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 1/23/2024 |
IVA Inventiva | $3.58
-0.1% | 1/5/2024 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Inventiva (NASDAQ:IVA) on 1/5/2024 |
RCKT Rocket Pharmaceuticals | $3.03
+8.0% | 12/26/2023 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 12/26/2023 |
TARS Tarsus Pharmaceuticals | $62.04
+0.3% | 12/26/2023 | | Reiterated Rating | | Outperform | 00.00% | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 12/26/2023 |
